株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬物依存症:パイプライン製品の分析

Drug Addiction - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251560
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
薬物依存症:パイプライン製品の分析 Drug Addiction - Pipeline Review, H2 2015
出版日: 2015年10月28日 ページ情報: 英文 95 Pages
概要

薬物依存症は物質依存症とも呼ばれており、破壊的パターンに至った場合には、その物質への耐性や依存脱却に多大な困難が伴うようになります。薬物依存症患者の主な症状・行動として、薬物の頻繁な利用により、職場・学校・家庭でなすべき必要な行動が取れなくなる、不眠症、睡眠リズムの不規則化、異常な怠惰感、拒食症/過食症、食事行動の変化、手のひらの体温低下・発汗、手の振るえ、目の充血・涙目、瞳孔拡張/縮小、呼吸・人体・服から異臭がする、などが挙げられます。

当レポートでは、世界各国での薬物依存症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

薬物依存症の概要

治療薬の開発

  • 薬物依存症向けパイプライン製品:概要
  • 薬物依存症向けパイプライン製品:比較分析

各企業で開発中の薬物依存症治療薬

大学/研究機関で研究中の薬物依存症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

薬物依存症治療薬:開発中の製品の一覧(企業別)

薬物依存症治療薬:研究中の製品の一覧(大学/研究機関別)

薬物依存症治療薬の開発に従事している企業

  • Gilead Sciences, Inc.
  • Aphios Corporation
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.
  • Biotie Therapies Corp.
  • Camurus AB
  • Curemark, LLC
  • Rottapharm SpA
  • Omeros Corporation
  • Immunovaccine, Inc.
  • 杏林製薬
  • D&A Pharma SAS
  • Embera NeuroTherapeutics, Inc.
  • Lightlake Therapeutics Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • LondonPharma Ltd.

薬物依存症:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 塩酸ネピカスタット
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • イブジラスト
  • 塩酸ブプレノルフィン
  • TV-1380
  • カンナビジオール
  • オキサゼパム+メチラポン
  • SKL-N05
  • LT-22
  • ASB
  • メタドン
  • GS-6673
  • ドロナビノール
  • ADX-88178
  • ADX-71441
  • OMS-527
  • コカイン中毒向けワクチン
  • コカイン中毒向けワクチン
  • MH-6ワクチン
  • 薬物依存症向けワクチン
  • イボガインのアナログ(類似体)
  • コカイン中毒・コカイン乱用向けDAT阻害用小分子
  • 中枢神経系(CNS)疾患・代謝障害向け5HT2修飾用小分子
  • CM-1212
  • methoxycoronaridine
  • がん・コカイン依存症向けBRD阻害用小分子
  • CR-5542シリーズ
  • 中枢神経系(CNS)疾患向けDAT・SERT阻害用小分子
  • 免疫疾患・中枢神経系(CNS)疾患・代謝障害向けδオピオイド受容体活性化用小分子
  • カンナビノイド乱用・薬物依存症向けCB1受容体阻害用小分子
  • 中枢神経系(CNS)疾患向けκオピオイド受容体活性化用小分子
  • 中枢神経系(CNS)疾患向けκオピオイド受容体阻害用小分子
  • 依存症向け医薬品

薬物依存症治療薬:パイプライン製品の最新動向

薬物依存症治療薬:開発が休止状態の製品

薬物依存症治療薬:開発が中止された製品

薬物依存症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7225IDB

Summary

Global Markets Direct's, 'Drug Addiction - Pipeline Review, H2 2015', provides an overview of the Drug Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Drug Addiction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Drug Addiction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Drug Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Drug Addiction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Drug Addiction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Drug Addiction - Overview
    • Pipeline Products for Drug Addiction - Comparative Analysis
  • Drug Addiction - Therapeutics under Development by Companies
  • Drug Addiction - Therapeutics under Investigation by Universities/Institutes
  • Drug Addiction - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Drug Addiction - Products under Development by Companies
  • Drug Addiction - Products under Investigation by Universities/Institutes
  • Drug Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aphios Corporation
    • Astellas Pharma Inc.
    • Curemark, LLC
    • Embera NeuroTherapeutics, Inc.
    • Immunovaccine, Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Lightlake Therapeutics Inc.
    • Omeros Corporation
    • Rottapharm SpA
    • Saniona AB
    • Teva Pharmaceutical Industries Limited
  • Drug Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (oxazepam + metyrapone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-2905 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-1212 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-5542 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Dependence - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EROA-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JQ-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-22 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MC-100093 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-S2359 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target 5HT2 for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TV-1380 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cocaine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Methamphetamine Addiction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Drug Addiction - Recent Pipeline Updates
  • Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Aug 13, 2015: Saniona Announces That FDA Has Approved The IND For NS2359 In Cocaine Addiction
      • Jun 16, 2015: MediciNova Announces New Article Published on MN-166 in Addiction Biology
      • May 28, 2015: Embera NeuroTherapeutics Initiates Phase 1 Clinical Trial to Test EMB-001 as a Novel Treatment for Addictions
      • Apr 10, 2015: HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction
      • Sep 23, 2014: Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy
      • Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction
      • Jun 18, 2013: MediciNova Announces Presentation Of Preliminary Results From Phase Ib Study Of MN-166 In Methamphetamine Addiction At 75th Annual Meeting Of CPDD
      • Feb 25, 2013: MediciNova's MN-166 Receives Fast Track Designation From FDA For Treatment Of Methamphetamine Dependence
      • Jan 18, 2013: Research team including Dr Gianluca Baio funded by the MRC
      • Jan 03, 2013: MediciNova Provides Development Update On MN-166
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Drug Addiction, H2 2015
  • Number of Products under Development for Drug Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2015
  • Drug Addiction - Pipeline by Aphios Corporation, H2 2015
  • Drug Addiction - Pipeline by Astellas Pharma Inc., H2 2015
  • Drug Addiction - Pipeline by Curemark, LLC, H2 2015
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2015
  • Drug Addiction - Pipeline by Immunovaccine, Inc., H2 2015
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Drug Addiction - Pipeline by Lightlake Therapeutics Inc., H2 2015
  • Drug Addiction - Pipeline by Omeros Corporation, H2 2015
  • Drug Addiction - Pipeline by Rottapharm SpA, H2 2015
  • Drug Addiction - Pipeline by Saniona AB, H2 2015
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Drug Addiction Therapeutics - Recent Pipeline Updates, H2 2015
  • Drug Addiction - Dormant Projects, H2 2015
  • Drug Addiction - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Drug Addiction, H2 2015
  • Number of Products under Development for Drug Addiction - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top